AstraZeneca’s Tezspire (tezepelumab) Receives EC’s Approval for the Treatment of Severe Asthma
Shots:
- The EC has approved Tezspire as an add-on maintenance treatment in patients aged ≥12yrs. with sev. asthma
- The approval was based on the (PATHFINDER) trial program incl. P-III (NAVIGATOR) trial evaluating Tezspire vs PBO when added to standard therapy in adults aged 8–80yrs. & adolescents aged 12–17yrs. with sev. uncontrolled asthma
- The results showed superiority across 1EPs & 2EPs, reduction in asthma exacerbations across the P-II (PATHWAY) & P-III (NAVIGATOR) trials including a broad population of sev. asthma patients irrespective of key biomarkers incl. blood eosinophil counts, allergic status & FeNO, no clinical differences b/w Tezspire & PBO were observed
Ref: Astrazeneca | Image: Astrazeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
